An investigational transcatheter mitral valve replacement (TMVR) device helped reduce mitral regurgitation to zero or trace levels in 98.7 percent of patients, according to 30-day follow-up data from the first 100 people scheduled to be treated with Abbott’s Tendyne system.

DUBLIN and PARIS — May 24, 2018 — Investigators today unveiled clinical data from the independently run Onyx 1-Month OCT Study, which showed strong early vessel healing in a patient population that contained a high percentage of patients with complex coronary artery disease who were implanted with the Resolute Onyx(TM) DES at one-month follow-up.

Assessment of coronary physiology to guide revascularization decisions has been linked to lower adverse event rates than using angiography alone, but the adoption of techniques such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) continues to lag behind guideline recommendations.

Two late-breaking clinical trials presented May 23 at EuroPCR in London demonstrated the ability of renal denervation to significantly lower patients’ blood pressures, regardless of whether they were taking antihypertensive medications.

At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

Edwards Lifesciences has received CE mark approval for its Cardioband Tricuspid Valve Reconstruction System, making it the first commercially available transcatheter therapy to treat tricuspid valve heart disease.